Risk Management


<< Back
Share
 Print

SYFOVRE™ (Pegcetacoplan) Consent

May 9, 2023

Dear OMIC Insureds:

We are pleased to announce the release of a consent form for FDA-approved SYFOVRE (Pegcetacoplan)

treatment for Geographic Atrophy, a form of Dry Age-Related Macular Degeneration.

If you have questions, contact us for confidential risk management advice at riskmanagement@omic.com

or call us at 1-800-562-6642 and enter 4 for Risk Management.

Sincerely,

Michelle Pineda, MBA
OMIC Risk Manager

CONFIDENTIALITY NOTICE: This correspondence is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this e-mail or the information herein by anyone other than the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, is prohibited. If you have received this e-mail in error, please notify us at riskmanagement@omic.com and destroy the original message and all copies.
_________________________________________________

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



Six reasons OMIC is the best choice for ophthalmologists in America.

Leader in the industry.

A-rated by AM Best, OMIC is consistently ranked among the top malpractice insurance companies in America for financial stability. No other carrier has matched OMIC's consistent financial performance with regard to both combined, operating, and surplus ratios, the most relevant financial measurements for an insurance carrier.

61864684